Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS). However, predictors of adherence are not well understood; past studies lacked lifestyle factors such as alcohol use and predictors of missed doses have not been evaluated. We examined both levels of non-adherence—stopping IMD and missing doses.Methods
This longitudinal prospective study followed a population-based cohort (n=199) of definite MS patients in Southern Tasmania (January 2002 to April 2005, source population 226 559) every 6 months. Baseline factors (demographic, clinical, psychological and cognitive) affecting adherence were examined by logistic regression and a longitudinal analysis (generalized estimating equation (GEE)).Results
Of the 97 patients taking an IMD (mean follow-up=2.4 years), 73% (71/97) missed doses, with 1 in 10 missing>10 doses in any 6-month period. Missed doses were positively associated with alcohol amount consumed per session (p=0.008). A history of missed doses predicted future missed doses (p<0.0005). Over one-quarter (27/97) stopped their current IMD, which was associated with lower education levels (p=0.032) and previous relapses (p=0.05). No cognitive or psychological test predicted adherence.Conclusions
There were few strong predictors of missed doses, although people with MS consuming more alcoholic drinks per session are at a higher risk of missing doses. Divergent factors influenced the two levels of non-adherence indicating the need for a multifaceted approach to improving IMD adherence. In addition, missed doses should be assessed and incorporated into clinical trial design and clinical practice as poor adherers could impact on clinical outcomes. Copyright © 2008 John Wiley & Sons, Ltd.